Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC (GSK)

115
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

GlaxoSmithKline: European Commission Authorizes Nimenix

04/27/2012 | 08:24am US/Eastern
Recommend:
0

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
Recommend :
0
React to this article
Latest news on GLAXOSMITHKLINE PLC
1d ago GLAXOSMITHKLINE : Business: Agenda: A suitable case for treatment: MAKING THE NE..
1d ago GLAXOSMITHKLINE : Directors Buy Shares (DIRECTOR DEALINGS)
3d ago GLAXOSMITHKLINE : Agenda A suitable case for treatment: BY NICK FLETCHER: MAKING..
4d ago GLAXOSMITHKLINE : Executives Acquire Shares, ADSs (DIRECTOR DEALINGS)
4d agoDJGLAXOSMITHKLINE : 2Q 2014 -- Forecast
4d ago China to hold public trial of couple who worked for GSK
5d ago GLAXOSMITHKLINE : China to hold public trial of foreign couple who worked for GS..
5d ago GLAXOSMITHKLINE : Trametinib (Mekinist™) and dabrafenib (Tafinlar™) ..
5d ago GLAXOSMITHKLINE : MEK/BRAF combination phase III study update
5d agoDJGLAXOSMITHKLINE : Melanoma Drug Study Shows Favorable Results
Advertisement
Chart
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Income Statement Evolution
GlaxoSmithKline plc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF